Mapletree Logistics Trust (SGX: M44U): FY2025/26 Performance & Valuation Analysis

Logistics REITReal EstateDistribution per UnitLeverageAsia-PacificValuationKey RisksSGX

A visual brief on Mapletree Logistics Trust's FY2025/26 performance and valuation — covering its Asia-Pacific logistics portfolio backed by Mapletree/Temasek, the de-rating in distribution per unit (DPU) amid currency headwinds and rising interest costs, gross revenue and aggregate leverage trends, comparative profitability and debt metrics, valuation versus NAV, geographic and concentration risks, and disciplined asset rejuvenation.

Buy Me a Coffee Back to Library

Want a company covered next?

Suggest a public company for a future OnePage Alpha visual brief. Requests help guide coverage, but do not influence conclusions.

Request a Company

Inside the brief

What this brief covers

Business model

What the company does and how it makes money.

Financial highlights

Revenue, profit, margins, and key operating numbers.

Cash flow quality

Whether accounting profit is supported by cash generation.

Accounting observations

Important notes, adjustments, and disclosure items.

Key risks

Business, funding, operational, and execution risks to monitor.

Questions for management

Practical questions investors can ask before going deeper.

Related briefs

Sanli Environmental Limited

Singapore · Environmental Engineering

Sanli Environmental Limited (SGX: 1E3): FY2026 Financial & Operational Dashboard

A visual brief on Sanli Environmental's FY2026 financial and operational dashboard — covering its Singapore-based water and waste-management engineering business across its EPC, O&M, and emerging-business segments, revenue drivers and geographic exposure, negative operating cash flow and contract-asset build-up, interest coverage and liquidity stress, key risks and accounting observations, and capital-allocation considerations.

Environmental EngineeringWater & WasteCash FlowLiquidityContract AssetsAccounting ObservationsKey RisksSGX

View Brief

42C · SGX19 Jun 2026

iX Biopharma Ltd.

Singapore · Healthcare

Corporate Analysis: iX Biopharma Ltd. (SGX: 42C)

A visual brief on iX Biopharma's FY2025–9M2026 corporate analysis — covering its proprietary sublingual WaferiX drug-delivery platform, the strategic pivot toward US government contracting, financial performance and cash flow, capital structure and dilution, accounting and disclosure observations, and key risks.

HealthcarePharmaceuticalsTurnaroundDilutionCash FlowAccounting ObservationsSGXCatalist

View Brief

A31 · SGX19 Jun 2026

Addvalue Technologies Ltd.

Singapore · Satellite Communications

Equity Research Snapshot: Addvalue Technologies Ltd. (SGX: A31)

A visual brief on Addvalue Technologies’ FY2026 reported turnaround, highlighting revenue growth, operating cash flow improvement, de-leveraging, order book visibility, customer concentration, capitalized development costs, and valuation/event-risk considerations.

Satellite CommunicationsTurnaroundCash FlowDe-leveragingCustomer ConcentrationAccounting ObservationsSGX

View Brief

Important disclaimer

OnePage Alpha is an educational research project. Content is based on public company disclosures and is provided for informational purposes only. Nothing on this site is financial advice, investment advice, or a recommendation to buy, sell, or hold any security. Readers should verify figures from original source documents and consult a licensed financial adviser where appropriate.